Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of MK-2010 alone or in combination for advanced solid tumors
MOH_2026-10-21_017097Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-299 in gastric cancer (GC), esophagogastric junction cancer, colorectal cancer (CRC) and 7 more (8 arms), sponsored by Merck & Co. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
LM-299
03
Conditions
gastric cancer (GC)esophagogastric junction cancercolorectal cancer (CRC)esophageal cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on MOH_2026-10-21_017097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-21_017097.